Archives of Medical Research
Volume 41, Issue 3 , Pages 162-169 , April 2010

Sensitization of Osteosarcoma Cell Line SaOS-2 to Chemotherapy by Downregulating Survivin

  • Jun Zou

      Affiliations

    • Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
    • These authors contributed equally to this work.
    • ,
  • Minfeng Gan

      Affiliations

    • Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
    • These authors contributed equally to this work.
    • ,
  • Nana Mao

      Affiliations

    • Department of Pharmacy, Suzhou School of Medial Science and Technology, Suzhou, Jiangsu, China
    • ,
  • Xuesong Zhu

      Affiliations

    • Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
    • ,
  • Qin Shi

      Affiliations

    • Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
    • ,
  • Huilin Yang

      Affiliations

    • Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
    • Corresponding Author InformationAddress reprint requests to: Huilin Yang, MD, Chairman & Professor, Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, 188 Shizi St., Suzhou, Jiangsu 215006, China; Phone: +86-512-67780101; FAX: +86-512-67780999

Received 24 September 2009 ,Accepted 7 February 2010.

References 

  1. Desandes E. Survival from adolescent cancer. Cancer Treat Rev. 2007;33:609–615
  2. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600–1606
  3. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001;37:2030–2039
  4. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790
  5. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007;67:7308–7318
  6. Dass CR, Choong PF. Gene therapy for osteosarcoma: steps towards clinical studies. J Pharm Pharmacol. 2008;60:405–413
  7. Lamoureux F, Trichet V, Chipoy C, et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther. 2007;7:169–181
  8. Yin D, Jia T, Gong W, et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol. 2008;33:253–259
  9. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18:609–615
  10. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114:1117–1127
  11. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004;279:34087–34090
  12. Shin S, Sung BJ, Cho Y, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117–1123
  13. Vong QP, Cao K, Li HY, et al. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 2005;310:1499–1504
  14. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  15. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54
  16. Wang W, Luo H, Wang A. Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol. 2006;93:578–584
  17. Osaka E, Suzuki T, Osaka S, et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem. 2006;39:95–100
  18. Trieb K, Lehner R, Stulnig T, et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 2003;29:379–382
  19. Liang X, Da M, Zhuang Z, et al. Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int. 2009;33:119–124
  20. Li QX, Zhao J, Liu JY, et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006;5:860–866
  21. Ko S, Yuen WF, Fung KP, et al. Reversal of TNF-alpha resistance by hyperthermia: role of mitochondria. Life Sci. 2000;67:3113–3121
  22. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential in apoptosis; an update. Apoptosis. 2003;8:115–128
  23. Peñuelas S, Noé V, Ciudad CJ. Modulation of IMPDH2; survivin; topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J. 2005;72:696–710
  24. Olie RA, Simões-Wüst AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805–2809
  25. Wang L, Zhang GM, Feng ZH. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line. Acta Pharmacol Sin. 2003;24:1235–1240
  26. Zhang W, Chen X, Qiu F. An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy. J Huazhong Univ Sci Technol Med Sci. 2003;23:387–391
  27. Hayashi N, Asano K, Suzuki H, et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate. 2005;65:10–19
  28. Kojima H, Iida M, Yaguchi Y, et al. Enhancement of cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg. 2006;132:682–685
  29. Van Valen F, Fulda S, Schäfer KL, et al. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer. 2003;107:929–940
  30. Lens SM, Wolthuis RM, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J. 2003;22:2934–2947
  31. Cassano WF, Graham-Pole J, Dickson N. Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer. 1991;68:1899–1902
  32. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol. 2008;9:1002–1011
  33. Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol. 2008;414:13–21

PII: S0188-4409(10)00097-4

doi: 10.1016/j.arcmed.2010.04.006

Archives of Medical Research
Volume 41, Issue 3 , Pages 162-169 , April 2010

Article Tools

* Image Usage & Resolution